Jazz Pharmaceuticals and AbCellera announced a preclinical research collaboration to discover next-generation T-cell engaging (TCE) multispecific antibodies aimed at GI cancers and other solid tumors. Jazz will pay $56 million upfront to AbCellera, with option and milestone payments that could reach $792 million for each program Jazz exercises. AbCellera will run discovery and early-stage research for two initial programs, with a third planned within 12 months. The deal adds to a crowded race to broaden TCEs beyond hematologic cancers, with both companies emphasizing early functional assay work and an end-to-end discovery-to-manufacturing platform.